ArticleProbiotics and antimicrobial proteins2026
Screening, Purification and Partial Characterization of Bacteriocin Produced by Lactic Acid Bacteria with Potentials to Control Staphylococcus aureus.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lactic acid bacteria bacteriocins as novel antimicrobials against antibiotic-resistant Streptococcus pneumoniae in opthalamic infections.Molecular biology reports · 2026Article
- Impact of lactic acid bacteria andVeterinary and animal science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Staphylococcus aureus is a common foodborne pathogen, and its prevention and control has always been a hot topic of concern. The purpose of this study was to screen bacteriocin-producing lactic acid bacteria (LAB) and explore its antibacterial and antibiofilm activity against S. aureus. A total of 67 strains of lactic acid bacteria were isolated from fermented foods, and 9 strains with good antibacterial activity against S. aureus and Escherichia coli were screened out according to the inhibition zone experiment and identified by 16S rDNA sequencing. After acid neutralization, and catalase and protease treatment, it was found that Lactiplantibacillus plantarum 65 could produce a new bacteriocin. The cell-free supernatant (CFS) of L. plantarum 65 was separated and purified by organic solvent extraction, sephadex LH20, and reversed-phase high-performance liquid chromatography (RP-HPLC). The antibacterial active peptide obtained was a new type of bacteriocin with an amino acid sequence of KVKPLHA and a molecular weight of 791.5Da. The CFS of L. plantarum 65 showed antibiofilm activity against S. aureus and Listeria monocytogenes, with the highest inhibition rate reaching 83.07%. L. plantarum 65 isolated from fermented food products could produce novel bacteriocin with the ability to inhibit growth and biofilm formation of S. aureus. IMPACT STATEMENT: The obtained results highlight the potential of bacteriocin-producing L. plantarum 65 have dual potential for antibacterial and antibiofilm activity against S. aureus, and it can be used for the prevention and control contamination of S. aureus in food.
Indexed as
Identifiers
40768023What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.